Resumen
Definición
Anamnesis y examen
Principales factores de diagnóstico
- cough
- sputum production
- crackles, high-pitched inspiratory squeaks and rhonchi
- dyspnea
- fever
Otros factores de diagnóstico
- fatigue
- hemoptysis
- rhinosinusitis
- weight loss
- wheezing
- pleuritic chest pain
- clubbing
Factores de riesgo
- cystic fibrosis
- host immunodeficiency
- previous infections
- congenital disorders of the bronchial airways
- primary ciliary dyskinesia
- alpha-1 antitrypsin deficiency
- connective tissue disease
- inflammatory bowel disease
- aspiration or inhalation injury
- focal bronchial obstruction
- tall, thin, white females, age 60 or over
- prematurity
Pruebas diagnósticas
Primeras pruebas diagnósticas para solicitar
- high-resolution chest CT
- CXR
- CBC
- sputum culture and sensitivity
- serum alpha-1 antitrypsin phenotype and level
- serum immunoglobulins
- sweat chloride test
- rheumatoid factor
- specific IgE or skin prick test to Aspergillus fumigatus
- serum HIV antibody
- nasal nitric oxide (NNO)
- pulmonary function tests
Pruebas diagnósticas que deben considerarse
- primary ciliary dyskinesia (PCD) testing
- cystic fibrosis transmembrane regulator (CFTR) protein gene mutation testing
- swallow study
- pH monitoring of esophagus
- 6-minute walk test
- tuberculosis testing
- diagnostic bronchoscopy with bronchoalveolar lavage
Algoritmo de tratamiento
initial presentation
acute exacerbation: mild to moderate underlying disease
acute exacerbation: severe underlying disease or not responding/resistant to initial antibiotics
3 or more exacerbations per year despite maintenance therapy
first or new isolation of Pseudomonas aeruginosa at outpatient review
Colaboradores
Autores
Anne E. O'Donnell, MD
Professor of Medicine
Chief, Division of Pulmonary, Critical Care and Sleep Medicine
The Nehemiah and Naomi Cohen Chair in Pulmonary Disease Research
Georgetown University Medical Center
Washington
DC
Divulgaciones
AEOD has received scientific consulting fees from the following companies: Bayer, Xellia, Horizon, Grifols, Insmed, and Electromed. AEOD is the Principal Investigator for trials sponsored by the following companies (research funding provided directly to Georgetown University): Bayer, Insmed, Aradigm, Parion, Zambon. AEOD has been a faculty member at the annual meetings of CHEST (American College of Chest Physicians), the American Thoracic Society, and the European Respiratory Society. AEOD is the author of a reference cited in this topic.
Agradecimientos
Dr Anne E. O'Donnell would like to gratefully acknowledge Dr Pamela J. McShane and Dr Sangeeta M. Bhorade, previous contributors to this topic.
Divulgaciones
PJM and SMB declare that they have no competing interests.
Revisores por pares
Philip W. Ind, BA (Cantab), MB BChir, MA (Cantab), FRCP
Emeritus Professor of Practice (Respiratory Medicine)
National Heart and Lung Institute
Imperial College London
London
UK
Divulgaciones
PWI declares that he has no competing interests.
Meg Coleman, MBBS, BSc, MRCP
Respiratory Consultant
Honorary Senior Clinical Lecturer
Imperial College Hospitals NHS Trust and National Heart and Lung Institute
London
UK
Divulgaciones
MC has received honoraria from Pfizer and Gilead for delivering educational sessions.
Amanda Messinger, MD, MS
Assistant Professor
Section of Pediatric Pulmonary and Sleep Medicine
Department of Pediatrics
Children's Hospital Colorado
University of Colorado Denver School of Medicine
Aurora
CO
Divulgaciones
AM declares that she has no competing interests.
Ware Kuschner, MD
Associate Professor of Medicine
Stanford University
Stanford
Staff Physician
US Department of Veterans Affairs
Palo Alto Health Care System
Palo Alto
CA
Divulgaciones
WK declares that he has no competing interests.
Agradecimiento de los revisores por pares
Los temas de BMJ Best Practice se actualizan de forma continua de acuerdo con los desarrollos en la evidencia y en las guías. Los revisores por pares listados aquí han revisado el contenido al menos una vez durante la historia del tema.
Divulgaciones
Las afiliaciones y divulgaciones de los revisores por pares se refieren al momento de la revisión.
Referencias
Artículos principales
Chang AB, Fortescue R, Grimwood K, et al. European Respiratory Society guidelines for the management of children and adolescents with bronchiectasis. Eur Respir J. 2021 Aug;58(2):2002990.Texto completo Resumen
Hill AT, Sullivan AL, Chalmers JD, et al. British Thoracic Society guideline for bronchiectasis in adults. Thorax. 2019 Jan;74(suppl 1):1-69.Texto completo Resumen
Polverino E, Goeminne PC, McDonnell MJ, et al. European Respiratory Society guidelines for the management of adult bronchiectasis. Eur Respir J. 2017 Sep 9;50(3):1700629.Texto completo Resumen
O'Donnell AE. Bronchiectasis - a clinical review. N Engl J Med. 2022 Aug 11;387(6):533-45. Resumen
Hill AT, Barker AF, Bolser DC, et al. Treating cough due to non-CF and CF bronchiectasis with nonpharmacological airway clearance: CHEST Expert Panel Report. Chest. 2018 Apr;153(4):986-93.Texto completo Resumen
Smith D, Du Rand I, Addy CL, et al. British Thoracic Society guideline for the use of long-term macrolides in adults with respiratory disease. Thorax. 2020 May;75(5):370-404.Texto completo Resumen
Artículos de referencia
Una lista completa de las fuentes a las que se hace referencia en este tema está disponible para los usuarios con acceso a todo BMJ Best Practice.

Diferenciales
- COPD
- Asthma
- Pneumonia
Más DiferencialesGuías de práctica clínica
- ACR appropriateness criteria: chronic dyspnea - noncardiovascular origin
- ACR appropriateness criteria: tracheobronchial disease
Más Guías de práctica clínicaFolletos para el paciente
Bronchiectasis: what is it?
Bronchiectasis: what are the treatment options?
Más Folletos para el pacienteVideos
Expiratory wheeze
Early inspiratory crackles
Mais vídeosConectar-se ou assinar para acessar todo o BMJ Best Practice
O uso deste conteúdo está sujeito ao nosso aviso legal